Literature DB >> 33352921

Convergent Evolution by Cancer and Viruses in Evading the NKG2D Immune Response.

Richard Baugh1, Hena Khalique1, Leonard W Seymour1.   

Abstract

The natural killer group 2 member D (NKG2D) receptor and its family of NKG2D ligands (NKG2DLs) are key components in the innate immune system, triggering NK, γδ and CD8+ T cell-mediated immune responses. While surface NKG2DL are rarely found on healthy cells, expression is significantly increased in response to various types of cellular stress, viral infection, and tumour cell transformation. In order to evade immune-mediated cytotoxicity, both pathogenic viruses and cancer cells have evolved various mechanisms of subverting immune defences and preventing NKG2DL expression. Comparisons of the mechanisms employed following virus infection or malignant transformation reveal a pattern of converging evolution at many of the key regulatory steps involved in NKG2DL expression and subsequent immune responses. Exploring ways to target these shared steps in virus- and cancer-mediated immune evasion may provide new mechanistic insights and therapeutic opportunities, for example, using oncolytic virotherapy to re-engage the innate immune system towards cancer cells.

Entities:  

Keywords:  NK cells; NKG2D ligands; NKG2D receptor; cancer; convergent evolution; immune evasion; immunotherapy; viruses

Year:  2020        PMID: 33352921      PMCID: PMC7766243          DOI: 10.3390/cancers12123827

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  4 in total

1.  Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity.

Authors:  Eric Alves; Emily McLeish; Pilar Blancafort; Jerome D Coudert; Silvana Gaudieri
Journal:  Front Immunol       Date:  2021-08-12       Impact factor: 7.561

2.  Integrated analysis of circulating immune cellular and soluble mediators reveals specific COVID19 signatures at hospital admission with utility for prediction of clinical outcomes.

Authors:  Iratxe Uranga-Murillo; Elena Morte; Sandra Hidalgo; Cecilia Pesini; Sandra García-Mulero; Jose L Sierra; Llipsy Santiago; Maykel Arias; Diego De Miguel; María Del Mar Encabo-Berzosa; Borja Gracia-Tello; Rebeca Sanz-Pamplona; Luis Martinez-Lostao; Eva M Galvez; Jose R Paño-Pardo; Ariel Ramirez-Labrada; Julian Pardo
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

3.  γδ T cell costimulatory ligands in antitumor immunity.

Authors:  Joseph M McGraw; Deborah A Witherden
Journal:  Explor Immunol       Date:  2022-02-24

Review 4.  Intracellular radar: Understanding γδ T cell immune surveillance and implications for clinical strategies in oncology.

Authors:  Anne B C Cherry; Nicholas A Gherardin; Hafiz I Sikder
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.